Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria - Takeaways - MDSpire

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

  • By

  • Gil Yosipovitch

  • Brian S. Kim

  • John Y. Koo

  • Zhen Chen

  • Simmi Wiggins

  • Joseph Zahn

  • Philip Sugerman

  • El-Bdaoui Haddad

  • Sonya L. Cyr

  • March 18, 2026

  • 0 min

Share

  • 1

    The article discusses the efficacy of dupilumab in alleviating itching across various dermatological conditions.

  • 2

    Clinical trials focused on atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

  • 3

    The safety summary table was corrected to accurately reflect treatment-emergent adverse events.

  • 4

    Dupilumab was compared with placebo and topical corticosteroids in the trials.

  • 5

    The corrections enhance the clarity and accuracy of the reported clinical trial data.

Original Source(s)

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

  • by Gil Yosipovitch, Brian S. Kim, John Y. Koo, Zhen Chen, Simmi Wiggins, Joseph Zahn, Philip Sugerman, El-Bdaoui Haddad, Sonya L. Cyr

  • March 18, 2026

Related Content

Efficacy of Upadacitinib in Treating Atopic Dermatitis in Sensitive Regions: Outcomes from a Multicenter Real-World Study on Hand, Head/Neck, and Genital Involvement

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.